Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Comment by fairweather1on Oct 16, 2014 3:21pm
119 Views
Post# 23035172

RE:RE:RE:RE:RE:RE:RE:Pending announcement ???

RE:RE:RE:RE:RE:RE:RE:Pending announcement ???
Regarding no business post Ford, I seem to recall mgt commenting on this once in the past.  I think there could be initially a partial distribution of net assets (cash) to shareholders after Ford wind down, with "some" money set aside for litigation costs...don't forget that an annual meeting will happen a few months after Ford wind down, so if mgt is being frivolous (eg:  paying numerous redundant business managers after Ford), they will likely get voted out at that time, would they not? 


Also, Mr Nutt holds a lot of stock, and current mgt has been quite shareholder friendly.  Look at the dividends, both regular and special, in the last while.  So his interests should be aligned -- somewhat -- with ours.

I think the bigger fear is mgt making a bad decision in buying a new business, given the general state of manufacturing in north america.  But its not like they can afford to buy (with leverage) a big business, so to get something large enough to justify continuance as a public firm, I think they would spend most/all of their cash, and would therefore have to be profitable in short order to pay salaries etc.  Bankers are not stupid like government, so AM is not going to get the kind of ongoing financial backing that the automakers have gotten. 

 Pickings are slim, but I'll also say that AM specializes in efficiency and timeliness, something that some companies/mgrs are lacking.  Could be quite the thrill ride.
Bullboard Posts